Loxo Oncology, Inc. clinical trial pipeline

2 trials changed in the last 30 days: 0 stopped, 2 with notable changes, 0 with minor changes only.

1. Notable

   BRUIN-MCL-321 · BTK Inhibitor LOXO-305 Versus Approved BTK…BRUIN-MCL-321 · BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs · Mantle Cell Lymphoma (MCL)

   Primary completion pushed from Jan 2027 to Nov 2027

   Also in this update: Study completion pushed from Apr 2028 to Jun 2030

   Loxo Oncology, Inc.·Phase 3· NCT04662255· Registry history of NCT04662255 on ClinicalTrials.gov (opens the registry)

   Sep 23, 2026

2. Notable

   BRUIN-CLL-313 · Pirtobrutinib (LOXO-305) Versus Bendamustine…BRUIN-CLL-313 · Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) · Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

   Primary endpoint(s) modified

   Also in this update: Results posted: Sep 25, 2026

   Loxo Oncology, Inc.·Phase 3· NCT05023980· Registry history of NCT05023980 on ClinicalTrials.gov (opens the registry)

   Sep 25, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.